1. Beyea SC, Nicoll LH (1996) Back to basics. Administering i.m. injections the right way. Am J Nurs 96: 34–35
2. Crewe HK, Ellis SW, Lennard MS, Tucker GT (1997) Variable contribution of cytochrome P450 2D6, 2C9 and 3A4 to the hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53: 171–178
3. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE, (1994) Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408–414
4. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 inhibition. Clin Pharmacokinet 38: 41–57
5. Harrison M, Laight A, Clarke DA, Giles P, Yates R (2003) Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. Proc ASCO 22: 45 abstract 311